Drug Type Monoclonal antibody |
Synonyms BGB A3055, BGB-A3055 |
Target |
Action inhibitors |
Mechanism CCR8 inhibitor(C-C motif chemokine receptor 8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Phase 1 | United States | 08 Jan 2024 | |
| Esophageal Squamous Cell Carcinoma | Phase 1 | China | 08 Jan 2024 | |
| Esophageal Squamous Cell Carcinoma | Phase 1 | Australia | 08 Jan 2024 | |
| Esophageal Squamous Cell Carcinoma | Phase 1 | France | 08 Jan 2024 | |
| Hepatocellular Carcinoma | Phase 1 | United States | 08 Jan 2024 | |
| Hepatocellular Carcinoma | Phase 1 | China | 08 Jan 2024 | |
| Hepatocellular Carcinoma | Phase 1 | Australia | 08 Jan 2024 | |
| Hepatocellular Carcinoma | Phase 1 | France | 08 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | United States | 08 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | China | 08 Jan 2024 |






